Observation of Cough Variant Asthma Treated in Combination of Chanqin Granules.

• Status: Unknown status
• Trial end date: 2019-06-30
• Target enrollment: 0
• Participant gender: All

Summary

This single-center, randomized, double-blind, placebo-controlled trial was undertaken at an outpatient clinic in Shuguang Hospital. Newly diagnosed cough variant asthma adult patients with the T.C.M. pattern of pathogenic-wind are randomly divided into treatment and control group, with 60 patients in each group. Clinical observation of the Respiratory Impedance and Inflammation in Cough Variant Asthma adults reated in Combination of Chanqin Granules.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Shanghai University of Traditional Chinese Medicine
• Treatments: Budesonide; Budesonide, Formoterol Fumarate Drug Combination; Formoterol Fumarate

Criteria

Inclusion Criteria:

1. Diagnosis of cough variant asthma according to Western medicine

2. Diagnosis of cough with pathogenic wind syndrome according to TCM

3. Aged between 18 to 70 years, regardless of gender, race or educational and economic status

4. The cough symptom should last for at least 8 weeks

4. Willingness to participate and to sign the informed consent form

Exclusion Criteria:

1. Patients with history of smoking (or quite smoking for less than 6 months)

2. Systemic use of corticosteroids in the past 4 weeks

3. Upper or lower respiratory tract infection in the past 4 weeks

4. Incapable of corporation with spirometry and FeNO test

5. Other chronic respiratory disease eg: COPD, pulmonary cirrhosis

6. Women who are pregnant or preparing to become pregnant or breast feeding women